Globenewswire·2025-12-16 12:15Core Viewpoint - Royalty Pharma has acquired a royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million, indicating a strategic investment in promising cancer therapies [1][4]. Group 1: Acquisition Details - Royalty Pharma is acquiring a low-single digit royalty on worldwide net sales for both neladalkib and zidesamtinib, with the expected royalty duration extending through approximately 2041 to 2042 [4]. - The total acquisition cost is up to $315 million, sourced from an undisclosed third party [1][4]. Group 2: Product Information - Neladalkib is being developed for ALK mutation-positive non-small cell lung cancer (NSCLC), while zidesamtinib targets ROS1 mutation-positive NSCLC [2]. - Both therapies aim to provide a best-in-class combination of efficacy and tolerability [2]. - Positive pivotal results for neladalkib have been reported, showing durable activity and a well-tolerated safety profile in TKI pre-treated patients [3]. - Zidesamtinib is under review by the U.S. FDA, with an action date set for September 18, 2026, for TKI pre-treated patients [3]. Group 3: Market Projections - Analyst consensus projects sales of approximately $3.5 billion for neladalkib and $1.9 billion for zidesamtinib by 2035 [3].